Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership
Crown Bioscience, a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005025/en/
Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years serving in a variety of operational and commercial leadership positions, and most recently served as Senior Vice President, Commercial and Strategic Development. (Photo: Business Wire)
Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years serving in a variety of operational and commercial leadership positions, and most recently served as Senior Vice President, Commercial and Strategic Development.
Building on the company’s continued growth, three new roles have been created within the commercial team and will report to Mr. Prosser. Alex Slater, who joined the company last year, has taken on added responsibility for APAC business development as Vice President of Global Business Development; Dr. Jonny McMichael has been appointed to Vice President of Client Experience and Enablement; and Dr. Achim Quandt has joined the company as Executive Director of Product Management.
“Crown Bioscience has grown significantly in recent years, consistently exceeding its annual growth target, and in FY21 we were delighted to record bookings growth of over 40%,” said Armin Spura, CEO. “With these changes announced today and under Michael's continued leadership, we are confident we are putting in place a commercial team that optimally positions Crown Bioscience for our next phase of growth.”
Michael Prosser, CBO, stated: “It’s an honor to be asked to lead the next stage in Crown Bioscience’s commercial growth. Our success to date is directly attributable to our relentless focus on customer experience, product innovation, and setting new industry-leading quality standards, and I’m excited to be working closely with the new team and structure as we strive to continuously improve in all these areas.”
The company added more than four hundred new customers in FY21, and to meet increased customer demand, has accelerated investments in its global footprint, with renovations now complete in APAC laboratories, and notably the formation of a joint venture with sister company MBL in Japan. In Europe and the United States, parallel investments are also planned for site expansions and strategic acquisitions.
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https://www.crownbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.27.1.2023 07:00:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorization for investigational palovarotene as a treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP). In the E.U. there are currently only symptomatic treatments for FOP, which do not reduce the formation of extra-skeletal bone in patients with the condition. Ipsen will be requesting a re-examination of the CHMP opinion, based on scientific data available from the existing palovarotene clinical trial program. FOP causes permanent and continuous new bone formation in soft and connective tissues, like muscles, tendons and ligaments, a process known as heterotopic ossification (HO).1 Once formed, it is irreversible.1 The average age of diagnosis is 5 years old2 and ultimately FOP shortens the median life expectancy to 56 years as untimely death is
Green Steel Technology Company Boston Metal Announces $120M Series C Financing Led by ArcelorMittal27.1.2023 06:01:00 CET | Press release
Boston Metal, a company developing technology to fully decarbonize steel production, today announced the $120 million first close of Series C fundraising led by multinational steel company, ArcelorMittal S.A. (NYSE: MT). Microsoft's Climate Innovation Fund and SiteGround Capital also joined as new investors in this round, alongside current investors. ArcelorMittal’s lead investment was made through its XCarb® Innovation Fund. Commenting, Aditya Mittal, CEO, ArcelorMittal, said, “In Boston Metal, we are investing in a team that has made impressive progress over a relatively short period of time, developing a technology that has exciting potential to revolutionize steelmaking. In our extensive discussions with them, we have been impressed by the passion and vision they have to contribute to the decarbonization of steelmaking. They are an exciting and welcome addition to the XCarb® Innovation Fund’s portfolio.” Boston Metal’s patented Molten Oxide Electrolysis (MOE) process is being comme
Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project27.1.2023 06:00:00 CET | Press release
Toyota Tsusho Corporation ("Toyota Tsusho"), Internet Initiative Japan Inc. ("IIJ"), NEC Corporation ("NEC"), and NTT Communications Corporation ("NTT Com") announced today the conclusion of a contract with Uzbektelecom, a state-owned telecommunications operator in Uzbekistan, for a telecommunications infrastructure development project ("the Project") to provide data center and telecommunications infrastructure for an advanced data communication system ("the System"). Installation of the System is scheduled to begin in 2023 and the sequential launch of operations is expected to significantly improve the communications environment of Uzbekistan. 1. Background In response to the rapidly growing data communication demand driven by the digitalization of various industries, Uzbekistan is expanding its telecommunications infrastructure aimed at issues such as improving communications quality and closing the digital divide between urban and rural areas. In accordance with this background, the
Bermuda Risk Summit 2023 – 27 January Last Chance to Secure Early Bird Rate26.1.2023 18:44:00 CET | Press release
Potential attendees of the BermudaBusinessDevelopmentAgency’s (BDA) second annual Bermuda Risk Summit, being held at the Hamilton Princess & Beach Club from March 6-8, are reminded the early bird registration price will end tomorrow, Friday, 27 January. Included in the early bird price are keynote breakfasts, networking breaks and lunches, an evening seaside soiree, and an island lunch cruise. Overseas guests should also act before midnight on Monday, February 6 to secure special hotel room rates starting at $359 (plus tax). From February 7, hotel room rates will increase significantly, or be completely sold out, due to limited availability. To book your room please call 1-441-295-3000 or the Global Reservations Centre on 1-800-441-1414. Alternatively, click hereto reserve your room online. Please use the booking code: ‘BermudaRisk’ to take advantage of the preferred rate. The Bermuda Risk Summit, which has the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sp
Verimatrix Secure Delivery Platform Marks Its First Year with Billions of Video Viewership Licenses Served26.1.2023 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced its Verimatrix Secure Delivery Platform quickly reached billions of delivered video viewership licenses in less than a year since its launch. The company also debuts key enhancements that provide even greater value to media companies, content owners, streaming media providers and operators. As a single pane of glass experience, the Verimatrix platform secures enterprises by protecting and monitoring their content, applications and devices through a streamlined cloud-based solution that brings a highly noticeable combination of cost savings and efficiency while also maximizing agility for the content delivery process. Newly released enhancements include: Full Verimatrix XTD integration, including App Shield and threat monitoring – offering unmatched visibility into potentially dangerous enterprise threat blind spots Integration
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom